<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Nair, Girish M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Obtaining Optimal Results with Flecainide and Propafenone</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">This article reviews the role of flecainide and propafenone for treating atrial fibrillation (AF, as well as the effectiveness and side effects of the potassium channel blockers sotalol, dofetilide, and amiodarone for AF. Also discussed are the results from the ADONIS, EURIDIS, ATHENA, and PALLAS in regards to AF.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>